Drugs / Trifluridine/Tipiracil
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07491159 | Jul 2023 → Jun 2026 overdue | colorectal cancer | Tianjin Medical University Cancer Institute and Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07491159 ↗ |
| Known as | TAS-102 | “Trifluridine/Tipiracil(TAS-102)” NCT07491159 ↗ |